Dose Response Effects of Liraglutide (Saxenda) on Weight Loss among Overweight and Obese Individuals: A Three Arm Randomized Controlled Trial

Abstract

Introduction: The present is aimed to determine the effects of three different doses of Liraglutide (Saxenda) that are 0.6mg, 1.2mg and 1.8mg with and without exercises on obese population after 6 months of intervention. Methodology: A three arm randomized controlled trial was performed at Isra Univeristy Hospital, Hyderabad. A total of n=60 obese participants including both male and female were recruited and divided into two groups n=20 participants in each group. Each group was than further divided into two subgroups n=10 participants in each subgroup. Results: The analyses of the findings had revealed that n=22 participants included in the study were male whereas n=38 were female. The mean Body Mass Index (BMI) of the participants in group A at baseline was 29.95±1.35kg/m2, 30.21±1.56 kg/m2 and 29.54±2.33 kg/m2 in subgroup (i), (ii) and (iii) respectively whereas in group B the values of BMI at baseline were 30.25±1.56 kg/m2, 29.87±2.56 kg/m2 and 30.11±2.33 kg/m2 in subgroup (i), (ii) and (iii) respectively. In group C the values were 30.01±2.14 kg/m2, 28.59±2.22 kg/m2 and 30.58±1.98 kg/m2 in subgroup (i), (ii) and (iii) respectively. Conclusion: The findings revealed substantial differences in BMI and body fat percentage within each group from baseline through three and six months of intervention. Higher Liraglutide (Saxenda) dosages (1.8mg) resulted with greater decreases in BMI and body fat percentage than lower doses (0.6mg and 1.2mg). Keywords: obesity, body mass index, body fat percentage